Shares of Biogen Inc rose
4% in premarket trade on Monday as an unanimous backing of the
company s Alzheimer s drug Leqembi by the U.S. regulator s
advisers eased concerns that a traditional approval. | June 12, 2023
Cambridge, Mass. - JUNE 9, 2023 - Biogen Inc. announced today that NASDAQ has halted trading of the company s common stock. The U.S. Food and Drug. | June 9, 2023
A panel of expert advisers on Friday
unanimously agreed that a late-stage clinical trial of Eisai
and Biogen s Leqembi verified the benefit of
the treatment for Alzheimer s disease, clearing the way. | June 9, 2023
Staff reviewers of the U.S. Food and
Drug Administration said on Wednesday that Eisai
and Biogen s Alzheimer s drug, Leqembi, may still be
eligible for a full approval despite concerns of. | June 7, 2023
Staff reviewers of the U.S. drug
regulator said trial data on Eisai and Biogen s
Leqembi confirmed benefits of the early Alzheimer s
drug and the prospects of a full approval were unaffected by
higher. | June 7, 2023